Methods: We studied 26 pediatric patients with standard-risk AML who had cryopreserved leukemia samples from both diagnosis and EOI. Of these, 13 patients had detectable low-level MRD at EOI by MFC, while the remaining patients were MRD negative. Samples were thawed, and those with less than ...
Treatment for adults with acute lymphoblastic leukaemia requires improvement. UKALL14 was a UK National Cancer Research Institute Adult ALL group study that aimed to determine the benefit of adding the anti-CD20 monoclonal antibody, rituximab, to the therapy of adults with de novo B-precursor acute...
Even though treatment of acute myeloid leukemia (AML) with curative intent is not standardized worldwide, it always involves intensive induction chemotherapy with the aim of reaching a (morphologically) complete remission (CR) and subsequent risk stratified post-remission therapy. Except for acute promy...
One hundred and eight consecutive acute myeloid leukemia (AML) patients aged 60 or less treated with two different induction regimens were retrospectively analyzed. Induction regimen for the first 50 consecutive patients was DA3+7, and the following 58 patients received cladribine 5 mg/m2on days 1...
Pediatric standard-risk AML with fully matched sibling donors: to transplant in first CR or not? Bone Marrow Transplant. 2008;42(6):393–6.AGassas, SAfzal, M KIshaqi, TFinkelstein-Shechter, MRojas, ADupuis, LSung, JDoyle. (2008) Pediatric standard-risk AML with fully matched sibling ...
This book provides up-to-date information on key topics and issues in Pediatric Acute Myeloid Leukemia (AML), including the epidemiology, biology, diagnosis and treatment of particular forms of the disease, supportive care, and survivorship. The entire spectrum of clinical management on pediatric ...
Sorafenib + Standard Chemotherapy in Pediatric Patients With FLT3/ITD+ AMLdoi:10.1097/01.COT.0000899264.16618.52Dibash Kumar DasWolters Kluwer Health, Inc.Oncology Times
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric patients ...
The Children's Oncology Group (COG) Phase III clinical trial AAML1031 tested the hypothesis that the addition of bortezomib to standard chemotherapy would improve treatment outcomes in pediatric patients with newly diagnosed AML. Methods: The COG AAML1031 trial randomized patients younger than 30 ...
cancers Review Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation? Michael Leisch 1,2, Bettina Jansko 1,2,3, Nadja Zaborsky 1,2,3, Richard Greil 1,2,3 and Lisa Pleyer 1,2,3,* 1 Department of Internal Medicine III ...